{
    "symbol": "SPRO",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-30 22:11:06",
    "content": " Before we begin, I'd like to remind you that some of the information presented on this conference call contains forward-looking statements based on our current expectations, including statements about the future development and commercialization of SPR720, SPR206 and tebipenem HBr, and the design, initiation, timing, progress and results of the company's preclinical studies and clinical trials and its research and developmental programs, management's assessment of the results of such preclinical studies and clinical trials, the company's cash forecast and anticipated expenses and the sufficiency of its cash resources. It is my pleasure to now provide an overview of Spero's financial results for the fourth quarter and full year ended December 31, 2022. Research and development expenses for the year ended December 31, 2022, were $47.6 million compared to $64.5 million for the year ended December 31, 2021. General and administrative expenses for the year ended December 31, 2022 were $36.5 million compared to $41.7 million for the year ended December 31, 2021. Spero reported net income of $26.8 million for the fourth quarter and a full year net loss of $46.4 million for the year ended December 31, 2022 or net income of $0.55 and net loss of $1.23 per share of common stock, respectively. Net losses for the fourth quarter and year ended December 31, 2021, were $29.2 million and $89.8 million or $0.90 and $2.91 per share of common stock, respectively."
}